Who are Mediwound's investors?

Mediwound's investors include Clal Biotechnology Industries, Deep Insight, Gandyr Investments, Israel Biotech Fund, New Era Capital Partners, Point72 Ventures.

How much funding has Mediwound raised?

Mediwound has disclosed $30.5M raised across 2 rounds.

Where is Mediwound headquartered?

Mediwound is headquartered in Yavne.

Mediwound

NASDAQ: MDWD

Yavne · Israel corporation · 6 known investors

Find your way into Mediwound

MediWound is a biotechnology company developing enzymatic treatments that selectively remove eschar tissue while preserving healthy tissue for burns and chronic wounds. Its products include NexoBrid, an approved therapy for severe thermal burns, and EscharEx, a candidate for debridement of chronic and hard-to-heal wounds, serving hospitalized and wound care patients worldwide.

Biotech Healthtech Medical Devices

Founders & leadership

Boaz Gur-LavieChief Financial Officer

Sharon MalkaExecutive

Ety KlingerChief R&D officer

Tzvi PalashNamed on SEC filing

Assaf SegalNamed on SEC filing

Sharon KochanNamed on SEC filing

David FoxNamed on SEC filing

Board

Ofer GonenChief Executive Officer

Vickie R. DriverBoard director

Nissim MashiachBoard director

Stephen T. WillsBoard director

Nachum (Homi) ShamirBoard director

Investors · 6

Clal Biotechnology Industrieslisted by Clal Biotechnology IndustriesTel Avivvia Avi Fischer · inferred

Deep Insightlisted by Deep InsightTel Aviv

How we know: Deep Insight's portfolio page · Not right? Tell us

Gandyr Investmentslisted by Gandyr InvestmentsHerzliya

How we know: Gandyr Investments's portfolio page · Not right? Tell us

Israel Biotech Fundlisted by Israel Biotech FundRehovot

New Era Capital Partnerslisted by New Era Capital PartnersTel Aviv

How we know: the VCSheet dataset · Not right? Tell us

Point72 VenturesreportedNew York · $1M – $75M

How we know: a partner's Signal profile · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$30.5M disclosed across 2 rounds · 2022

▶$17.2MraisedOct 2022 · 10 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Yaron MeyerExecutive Officer
Tzvi PalashExecutive Officer
Vickie R. DriverDirector
Nachum (Homi) ShamirDirector
Sharon MalkaDirector
Boaz Gur-LavieExecutive Officer
Stephen T. WillsDirector
Ety KlingerExecutive Officer, Director
Assaf SegalDirector
Ofer GonenExecutive Officer
Lior RosenbergExecutive Officer
Nissim MashiachDirector
David FoxDirector
Sharon KochanDirector

Offering amount: $17.2M
Amount sold: $17.2M
Sales commissions: $981.7K
Placement agents: H.C. Wainwright & Co., LLC
First sale: Sep 2022
Incorporated: Corporation, Israel
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$13.3MraisedOct 2022 · 13 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Ety KlingerExecutive Officer, Director
Ofer GonenExecutive Officer
Boaz Gur-LavieExecutive Officer
Sharon MalkaDirector
Vickie R. DriverDirector
Tzvi PalashExecutive Officer
Nissim MashiachDirector
Stephen T. WillsDirector
Assaf SegalDirector
Nachum (Homi) ShamirDirector
Sharon KochanDirector
David FoxDirector
Yaron MeyerExecutive Officer
Lior RosenbergExecutive Officer

Offering amount: $13.3M
Amount sold: $13.3M
Sales commissions: $928K
Placement agents: H.C. Wainwright & Co., LLC
First sale: Sep 2022
Incorporated: Corporation, Israel
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Natrox20 shared keywordsAdvanced wound care therapy delivering continuous topical oxygen to accelerate healing.

Vendelux20 shared keywordsVendelux runs an AI-based event intelligence platform that helps B2B teams pick events, book meetings and attribute pipeline.

Smith+Nephew17 shared keywordsSmith+Nephew is a medical technology company that develops products for the repair, regeneration, and replacement of soft and hard tissue, including sports medicine solutions for treating sporting injuries. Its technology is used by surgeons to help patients recover and regain mobility.

Companies competing with Mediwound for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Mediwound do?: MediWound is a biotechnology company developing enzymatic treatments that selectively remove eschar tissue while preserving healthy tissue for burns and chronic wounds. Its products include NexoBrid, an approved therapy for severe thermal burns, and EscharEx, a candidate for debridement of chronic and hard-to-heal wounds, serving hospitalized and wound care patients worldwide.
Who are Mediwound's investors?: Mediwound's investors include Clal Biotechnology Industries, Deep Insight, Gandyr Investments, Israel Biotech Fund, New Era Capital Partners, Point72 Ventures.
How much funding has Mediwound raised?: Mediwound has disclosed $30.5M raised across 2 rounds.
Where is Mediwound headquartered?: Mediwound is headquartered in Yavne.